MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Compugen Ltd

Uždarymo kaina

1.74 0.58

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.73

Max

1.78

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-1.1M

-7.2M

Pardavimai

813K

2.3M

P/E

Sektoriaus vid.

60.333

40.527

Pelnas, tenkantis vienai akcijai

-0.08

Pelno marža

-314.405

Darbuotojai

74

EBITDA

-912K

-8.4M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+297.73% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-520M

166M

Ankstesnė atidarymo kaina

1.16

Ankstesnė uždarymo kaina

1.74

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Compugen Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-04 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-07-04 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-07-04 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-07-04 20:50; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2025-07-04 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-07-04 16:20; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2025-07-04 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-07-04 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-07-04 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-04 15:57; UTC

Rinkos pokalbiai

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

2025-07-04 15:49; UTC

Rinkos pokalbiai

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

2025-07-04 15:49; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

2025-07-04 15:49; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

2025-07-04 15:49; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole Received All Required Authorizations

2025-07-04 15:48; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

2025-07-04 15:47; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole: Agreement Was Announced on Dec. 19

2025-07-04 15:47; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

2025-07-04 15:46; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

2025-07-04 14:30; UTC

Įsigijimai, susijungimai, perėmimai

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

2025-07-04 13:53; UTC

Rinkos pokalbiai

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

2025-07-04 13:41; UTC

Rinkos pokalbiai

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

2025-07-04 13:41; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-07-04 13:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-04 12:37; UTC

Rinkos pokalbiai

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

2025-07-04 12:37; UTC

Rinkos pokalbiai

Fund Manager Roundup: U.S. Treasurys in Focus -2-

2025-07-04 12:30; UTC

Rinkos pokalbiai

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

2025-07-04 12:15; UTC

Rinkos pokalbiai

Targeted Tariffs Would Likely Support Dollar -- Market Talk

2025-07-04 12:13; UTC

Rinkos pokalbiai

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

2025-07-04 12:02; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-07-04 12:02; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

Akcijų palyginimas

Kainos pokytis

Compugen Ltd Prognozė

Kainos tikslas

By TipRanks

297.73% į viršų

12 mėnesių prognozė

Vidutinis 7 USD  297.73%

Aukščiausias 10 USD

Žemiausias 4 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Compugen Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

3

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

1.25 / 1.48Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Very Strong Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.